Basic Information
TAGRISSO TABLET 40MG
TABLET, FILM COATED
Regulatory Information
SIN15140P
December 15, 2016
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
Company Information
Active Ingredients
Strength: 40mg
Detailed Information
Contraindications
**4.3 Contraindications** None.
Indication Information
**4.1 Therapeutic indications** TAGRISSO (osimertinib) is indicated for: - the adjuvant treatment after tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. - the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. - the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR TKI therapy. (See Clinical efficacy and safety section – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_)